Economic Outcomes of Isavuconazole to Prevent Invasive Fungal Infection in Immunocompromised Adults: Initial Experience at an Academic Medical Center

BACKGROUND: Isavuconazole (ISA) is a once-daily, extended-spectrum triazole approved for treatment of invasive aspergillosis and mucormycosis. The pharmacokinetic profile, daily dosing, lack of therapeutic drug monitoring (TDM) and reduced cost make ISA a promising option for use as prophylaxis for...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Open Forum Infect Dis
Hoofdauteurs: Kowalewska, Christina A, Tallman, Gregory B, Pham, Aaron N, Lewis, James S
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2017
Onderwerpen:
Abstracts
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630875/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1264
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items